Enclomiphene Citrate vs Testosterone Enanthate: What to Do When One Fails

How Each Drug Actually Works

Enclomiphene citrate and testosterone enanthate raise serum testosterone, but through completely opposite mechanisms. Enclomiphene blocks hypothalamic and pituitary estrogen receptors, removing the negative-feedback brake on gonadotropin release. Testosterone enanthate bypasses the entire hypothalamic-pituitary-gonadal (HPG) axis and delivers testosterone directly. That single mechanistic difference determines which patients respond, which fail, and how to switch safely.

Enclomiphene: Working With the Axis

Enclomiphene is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus, suppressing the feedback that normally dampens GnRH pulsatility. LH and FSH rise, which signals the Leydig cells to produce more testosterone endogenously. Because the testes remain active, intratesticular testosterone stays high enough to support spermatogenesis.

In a 124-man randomized trial published in BJU International, Kim et al. Showed that 25 mg/day of enclomiphene raised mean serum testosterone from 230 ng/dL to 430 ng/dL at 3 months while maintaining LH and FSH above baseline, compared to exogenous testosterone gel, which suppressed LH to near-undetectable levels 1.

Testosterone Enanthate: Replacing the Signal

Testosterone enanthate is a long-chain ester of testosterone. After IM injection, esterases in plasma and muscle slowly cleave the ester bond, releasing free testosterone over 7 to 10 days. Serum testosterone peaks around 24 to 72 hours post-injection and returns toward baseline by day 10 to 14 2.

The HPG axis reads rising serum testosterone as sufficient and suppresses LH, FSH, and GnRH. Intratesticular testosterone drops. Testicular volume typically decreases within 3 to 6 months of continuous therapy. That suppression is the price of reliable, dose-controlled T replacement.

Defining Failure: Labs First, Symptoms Second

"Failure" is not a patient reporting that he still feels tired. Failure has a biochemical definition, and treatment decisions must rest on repeat labs before any switch. A single low total testosterone reading, drawn outside the recommended morning window (7 to 10 a.m.) or during acute illness, does not constitute treatment failure.

Criteria for Enclomiphene Failure

Enclomiphene is considered to have failed when, after 90 days at 25 mg/day, morning total testosterone remains below 400 ng/dL on two separate draws, AND LH/FSH have risen (confirming the drug reached its pituitary target), yet testosterone is still low. That pattern means the testes cannot respond adequately, indicating primary hypogonadism. No SERM will fix a Leydig cell that is intrinsically impaired.

A secondary reason for apparent enclomiphene failure is poor absorption or non-adherence. Confirm pill-taking behavior and check serum LH before concluding the drug is ineffective.

Criteria for Testosterone Enanthate Failure

Testosterone enanthate fails most commonly in one of three ways. First, the dose is insufficient: trough testosterone (drawn just before the next injection) remains below 400 ng/dL despite 200 mg every 14 days, suggesting the dosing interval is too long for the individual's metabolism. Second, erythrocytosis or elevated hematocrit above 54% forces a dose reduction that drops testosterone into the symptomatic range. Third, persistent symptoms despite adequate trough levels (above 600 ng/dL) suggest the problem is not testosterone deficiency.

The Testosterone Trials (T-Trials, N=790, NEJM 2016) found that men randomized to testosterone gel achieving average levels of 824 ng/dL still reported incomplete resolution of energy and libido symptoms, reinforcing that not all symptoms in older hypogonadal men are testosterone-driven 2.

Who Should Start on Enclomiphene vs. Testosterone Enanthate

Matching the drug to the pathology at baseline prevents the most common failures. Secondary hypogonadism (low testosterone with inappropriately low or normal LH/FSH) responds to enclomiphene because the HPG axis is intact and just needs stimulation. Primary hypogonadism (low testosterone with elevated LH/FSH) means the testes are already receiving maximum stimulation and enclomiphene has nothing to amplify. Testosterone enanthate is the correct first-line choice there.

Age and Fertility Goals

Men under 40 who want to preserve fertility are almost always better started on enclomiphene or another SERM. Testosterone enanthate causes azoospermia or severe oligospermia in up to 75% of men within 6 months of continuous use, according to a World Health Organization contraceptive trial 3. Recovery of spermatogenesis after stopping testosterone enanthate takes a median of 6 months, and full recovery to pre-treatment sperm concentrations may take 12 to 24 months in some men.

Men over 50 with confirmed primary hypogonadism and no fertility concerns are reasonable candidates for testosterone enanthate as first-line treatment.

Obesity and Aromatase Activity

High adipose tissue mass increases aromatase activity, converting testosterone to estradiol at a faster rate. In obese men (BMI above 30), estradiol levels may already be suppressing LH before any drug is started. Enclomiphene can still work in this population, but the response is blunted. Weight loss before starting either therapy often produces clinically meaningful testosterone increases on its own, a point the Endocrine Society's 2018 clinical practice guideline on male hypogonadism emphasizes explicitly 4.

Switching From Enclomiphene to Testosterone Enanthate

When enclomiphene fails biochemically (LH/FSH elevated, testosterone still low), the switch to testosterone enanthate is straightforward and usually does not require a washout period.

Step-by-Step Protocol

1. Confirm failure with two morning testosterone draws at least one week apart, both below 400 ng/dL, with LH above 8 IU/L, indicating primary testicular insufficiency.
2. Stop enclomiphene. No taper is needed because enclomiphene is not suppressing the HPG axis.
3. Start testosterone enanthate at 100 mg IM every 7 days, or 200 mg IM every 14 days. Weekly injections produce less peak-to-trough variability. A meta-analysis of TRT injection frequency confirmed that weekly dosing keeps trough testosterone more consistently above 400 ng/dL compared with biweekly dosing 5.
4. Recheck total testosterone (trough draw), hematocrit, and PSA at 6 weeks and 12 weeks.
5. Adjust dose upward by 25 mg increments if trough remains below 400 ng/dL, or reduce interval from 14 days to 10 days before increasing the dose.

What to Monitor After Switching

Hematocrit is the most common adverse effect requiring dose adjustment on testosterone enanthate. A hematocrit above 54% (or hemoglobin above 18 g/dL) warrants dose reduction or temporary treatment interruption. Checking at 3 months and 6 months after initiation catches the rise before it becomes symptomatic.

Estradiol may rise as exogenous testosterone is aromatized. If estradiol climbs above 40 pg/mL alongside symptoms of gynecomastia or water retention, a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly may be added, though the Endocrine Society guideline cautions against routine use of aromatase inhibitors without confirmed elevated estradiol 4.

Switching From Testosterone Enanthate to Enclomiphene

This switch is more complex because exogenous testosterone has suppressed the HPG axis. Simply starting enclomiphene while continuing testosterone enanthate accomplishes little; the axis remains suppressed by the exogenous T.

The HPG Axis Recovery Window

After stopping testosterone enanthate, LH and FSH begin recovering within 2 to 4 weeks, but the axis may take 3 to 6 months to reach baseline gonadotropin pulsatility, particularly in men who have been on therapy for more than 2 years. A post-TRT testosterone of less than 200 ng/dL at 8 weeks off therapy, accompanied by LH still below 2 IU/L, suggests slow axis recovery. In that scenario, a short course of hCG (1,500 to 2,500 IU three times per week for 4 to 6 weeks) to directly stimulate Leydig cells can accelerate recovery before enclomiphene is introduced.

Who Should Consider the Switch Back

Younger men who started testosterone enanthate without adequate pre-treatment fertility counseling and who now want biological children are the most common group requesting this reversal. The switch is also reasonable for men who develop erythrocytosis or sleep apnea that worsens on exogenous testosterone, as enclomiphene does not drive these adverse effects to the same degree.

A practical decision framework: if a man's pre-TRT LH and FSH were normal or low (secondary hypogonadism pattern), the axis was intact before and likely can recover. If pre-treatment LH was already elevated, the testes were the primary failure point, and enclomiphene is unlikely to work after TRT cessation.

Enclomiphene Start Timing After Stopping Testosterone Enanthate

Starting enclomiphene too early (within 4 weeks of the last testosterone enanthate injection) is a common protocol error. Serum testosterone from the ester will still be present and may partially suppress LH response. Waiting until total testosterone falls below 300 ng/dL (typically 4 to 8 weeks after the last 200 mg injection) and LH begins to rise above 2 IU/L before starting enclomiphene at 12.5 mg/day gives the drug the best chance to amplify a recovering axis.

Recheck testosterone and LH at 6 weeks on enclomiphene. If testosterone has not reached 400 ng/dL and LH is above 6 IU/L, the testes are not responding adequately. That is the biochemical signal to return to testosterone enanthate rather than escalate enclomiphene.

Side-Effect Profiles and How They Drive the Switching Decision

Understanding the distinct adverse-effect profiles of both drugs helps predict which patients are likely to fail tolerability before they fail efficacy.

Enclomiphene Side Effects

Visual disturbances are the most medically significant adverse effect of clomiphene-class SERMs, occurring in roughly 1 to 2% of users. Patients should be instructed to stop the drug and seek ophthalmology evaluation if blurred vision or visual field changes develop. Mood changes, particularly irritability, occur less commonly with enclomiphene than with its zuclomiphene-containing parent compound clomiphene citrate, because the zuclomiphene isomer is largely responsible for CNS side effects.

Hot flashes are reported in a small fraction of men and typically resolve within weeks. Unlike testosterone enanthate, enclomiphene does not suppress endogenous testosterone production, does not raise hematocrit, and does not worsen obstructive sleep apnea.

Testosterone Enanthate Side Effects

The adverse effects most likely to force a treatment change are erythrocytosis (hematocrit above 54%), acne, injection-site discomfort, and worsening sleep apnea. Testicular atrophy is expected and reversible on cessation, but patients should be counseled before starting.

Cardiovascular risk on exogenous testosterone remains an active research area. The TRAVERSE trial (N=5,246, published NEJM 2023) found that testosterone therapy in middle-aged and older hypogonadal men with high cardiovascular risk did not increase major adverse cardiovascular events over a median 33-month follow-up, though the rate of pulmonary embolism and atrial fibrillation was modestly higher in the testosterone group 6. Clinicians managing men on testosterone enanthate with known cardiovascular disease should monitor hematocrit and blood pressure at every visit.

Combination Therapy: When Neither Drug Alone Is Enough

Some men on testosterone enanthate who want to restart fertility or prevent testicular atrophy are maintained on low-dose hCG (500 IU twice weekly) alongside their TRT. This is not a standard FDA-approved indication but is supported by data showing that hCG maintains intratesticular testosterone adequate for spermatogenesis even during exogenous testosterone suppression 7.

Combining enclomiphene with low-dose testosterone enanthate (50 to 75 mg/week) is a less-established approach used in clinical practice when a man has partial primary hypogonadism but still wants to preserve some HPG axis activity. Monitoring LH in this scenario confirms whether enclomiphene is adding meaningful stimulation on top of a partially suppressed axis.

Practical Lab Checklist Before Any Switch

Before switching in either direction, collect the following labs to avoid making the decision on incomplete data.

• Total testosterone (morning draw, two separate days)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH
• Estradiol (sensitive assay)
• Hematocrit and hemoglobin
• PSA (men over 40 or any man with prostate symptoms)
• SHBG (high SHBG lowers free testosterone even when total T appears adequate)
• Semen analysis if fertility is a concern

Thyroid dysfunction and hyperprolactinemia can mimic or compound hypogonadism. A TSH and prolactin level should be checked before committing to a permanent switch, especially if previous therapy produced only partial symptom relief. The Endocrine Society guideline specifies checking prolactin in any man with secondary hypogonadism to rule out a pituitary adenoma before starting testosterone therapy 4.

Dosing Adjustments That Prevent Premature Switching

Most "failures" on both drugs are actually dosing errors. Reviewing the dose before declaring failure saves time and avoids unnecessary transitions.

Enclomiphene Dosing Optimization

The starting dose of 12.5 mg/day is appropriate for most men, but some respond only at 25 mg/day. If testosterone at 6 weeks on 12.5 mg is below 350 ng/dL and LH has risen above 4 IU/L (confirming absorption), titrate up to 25 mg/day before concluding the drug does not work. Response plateaus above 25 mg/day; doses above 50 mg/day add side-effect risk without proportional testosterone gain.

Testosterone Enanthate Dosing Optimization

A trough testosterone below 400 ng/dL on 200 mg every 14 days almost always responds to shortening the interval to 10 days before increasing the dose. Shortening the interval rather than increasing the dose reduces peak-to-trough swings and lowers the risk of hematocrit elevation. Only after optimizing the interval should the per-injection dose be increased, and rarely above 250 mg per injection in a clinical (non-bodybuilding) TRT context.